Akebia Therapeutics Inc.’s filing revealed that its SVP, Chief Operating Officer Dahan Michel unloaded Company’s shares for reported $0.12 million on May 25. In the deal valued at $1.22 per share,95,478 shares were sold. As a result of this transaction, Dahan Michel now holds 574,037 shares worth roughly $ 0.76 million.
Then, Hadas Nicole R. sold 63,186 shares, generating $77,270 in total proceeds. Upon selling the shares at $1.22, the SVP, Chief Legal Officer now owns 524,344 shares.
Before that, Burke Steven Keith sold 63,567 shares. Akebia Therapeutics Inc. shares valued at $67,890 were divested by the SVP, Chief Medical Officer at a price of $1.07 per share. As a result of the transaction, Burke Steven Keith now holds 530,487 shares, worth roughly $0.71 million.
H.C. Wainwright upgraded its Akebia Therapeutics Inc. [AKBA] rating to a Buy from a a Neutral in a research note published on Friday. PT values the company’s stock at a premium of 64.53 to its Friday closing price.
Price Performance Review of AKBA
On Friday, Akebia Therapeutics Inc. [NASDAQ:AKBA] saw its stock fall -4.32% to $1.33. On the same session, the stock had its day’s lowest price of $1.31, but rose to a high of $1.41. Over the last five days, the stock has gained 15.65%. Akebia Therapeutics Inc. shares have risen nearly 130.50% since the year began. Nevertheless, the stocks have risen 265.08% over the past one year. While a 52-week high of $1.84 was reached on 08/01/23, a 52-week low of $0.24 was recorded on 04/05/23. SMA at 50 days reached $1.2718, while 200 days put it at $0.8809. A total of 1.88 million shares were traded, compared to the trading of 1.02 million shares in the previous session.
Levels Of Support And Resistance For AKBA Stock
The 24-hour chart illustrates a support level at 1.2900, which if violated will result in even more drops to 1.2500. On the upside, there is a resistance level at 1.3900. A further resistance level may holdings at 1.4500. The Relative Strength Index (RSI) on the 14-day chart is 49.38, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.0669, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 50.00%. Stochastics %K at 60.32% indicates the stock is a holding.
How much short interest is there in Akebia Therapeutics Inc.?
A steep rise in short interest was recorded in Akebia Therapeutics Inc. stocks on Aug 14, 2023, growing by 1.37 million shares to a total of 6.76 million shares. Yahoo Finance data shows the prior-month short interest on Jul 13, 2023 was 5.39 million shares. There was a rise of 20.27%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 3.68% of the overall stock float, the days-to-cover ratio (short ratio) rose to 2.9.
Akebia Therapeutics Inc. [AKBA] – Who Are The Largest Shareholders?
In filings from The Vanguard Group, Inc., it is revealed that the company now owns 7,751,064 shares, or roughly 4.17% of the outstanding AKBA shares. In other words, the investor’s shares have fallen by -4,699,843 from its previous 13-F filing of 12450907.0. Additionally, Acadian Asset Management LLC decreased -0.30% of its stake after which the total value it holdings stand at $12,458,790, while Renaissance Technologies LLC added 42.43% of its stake to hold $5.56 million in the firm. Over the last quarter, BlackRock Fund Advisors purchased 70,299 shares of Akebia Therapeutics Inc., while Millennium Management LLC bought 1,095,000 shares. At present, Geode Capital Management LLC is holding 1,772,977 shares valued at $2.96 million. Jacobs Levy Equity Management, In owned 1,346,032 shares of the company at the time of its most recent 13F filing, worth $2.25 million.
According to FactSet, Akebia Therapeutics Inc.’s share price will average $3.88 in the next year, based on opinions of analysts polled by the firm. This is up nearly 179.14 percent from its previous closing price of $1.39. Analysts expect Akebia Therapeutics Inc. stock to reach the higher price of $4.00, while the lowest price estimate is $3.75. However, 2 analysts have rated AKBA stock as a Buy in their predictions for 2023.